Compare Heron Therapeutics Inc (HRTX) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Modine Manufacturing Company — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while Modine Manufacturing Company trades at $184.4 (market cap $9.66B). The key difference: Modine Manufacturing Company is far larger — about 142× Heron Therapeutics Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Modine Manufacturing Company for 33 Days on average.
| HRTX | MOD | |
|---|---|---|
Market Cap | $68.01M | $9.66B |
Volume | 1,891,941 | 1,331,946 |
Sector | Health | Industrials |
52-Week High | $1.49 | $283.95 |
52-Week Low | $0.27 | $110.73 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $174.75M | $10.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Modine Manufacturing (MOD) trades at $182.00, down 3.93% on the day, amid a bearish technical signal and recent volatility following the completion of its Performance Technologies spin-off and merger with Gentherm. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 surpassing the $1.30 expectation. Analyst sentiment remains strongly positive with a consensus price target of $331.25, though technical indicators show selling pressure with key support at $177 and resistance at $187.
The outlook is mixed; strong analyst support and recent strategic moves like the spin-off suggest long-term growth potential, but near-term risks include integration challenges, a high P/E ratio of 67.87, and a projected decline in net profit margin for 2026. Investors should weigh solid fundamentals against current technical weakness and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
